Literature DB >> 26070505

VZV skin-test reaction, but not antibody, is an important predictive factor for postherpetic neuralgia.

Kyoko Imoto1, Aiko Okazaki1, Fumitake Onishi2, Yoshiyuki Miyazaki2, Masayuki Okeda2, Shuichiro Yano2, Yukiko Takao3, Yasuyuki Gomi2, Toyokazu Ishikawa2, Yoshinobu Okuno2, Yasuko Mori4, Hiroyasu Iso5, Koichi Yamanishi6, Hideo Asada7.   

Abstract

BACKGROUND: The decline of cell-mediated immunity (CMI) is thought to be related to the risk of postherpetic neuralgia (PHN) as well as herpes zoster (HZ). However, the relationship between immunological condition and the incidence of PHN is still unclear.
OBJECTIVE: We conducted a large-scale prospective cohort study to clarify the relationship between immunological factors for varicella-zoster virus (VZV) and the incidence of PHN.
METHODS: We carried out a cohort study on VZV immunity in a population living on an island cluster, Shozu County in Japan, and examined the people who developed HZ during a follow-up period of 3 years, with a focus on the relationship between cell-mediated and humoral immunity and the incidence of PHN. A total of 12,522 people over the age of 50 were enrolled in this study, and 401 registrants were diagnosed with HZ, including 79 PHN cases. We evaluated anatomical location and severity of skin lesion, acute pain severity, presence or absence of abnormal sensations, CMI assessed by VZV skin test, and VZV-specific antibody titer measured by serological tests.
RESULTS: The incidence of PHN was significantly associated with a weak response to the VZV skin test, as well as facial or lumbosacral localization of skin rash, severe skin lesion, severe acute pain, and presence of abnormal sensations, but not related to VZV-specific antibody titer.
CONCLUSION: The incidence of PHN is significantly associated with the decline of VZV-specific CMI, but not related to VZV-specific humoral immunity.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26070505     DOI: 10.1016/j.jdermsci.2015.05.011

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  6 in total

1.  Treatment of Postherpetic Neuralgia Using Narrow Band Ultraviolet B Radiation (UVB).

Authors:  Piotr Brzezinski; Ewelina Cywinska; Anca Chiriac
Journal:  Maedica (Buchar)       Date:  2015-09

2.  Association between treatment-related early changes in psychological factors and development of postherpetic neuralgia.

Authors:  Rie Koga; Keiko Yamada; Rie Ishikawa; Yasuhiko Kubota; Keisuke Yamaguchi; Masako Iseki
Journal:  J Anesth       Date:  2019-09-11       Impact factor: 2.931

3.  Usefulness of Inflammatory Markers for the Prediction of Postherpetic Neuralgia in Patients with Acute Herpes Zoster.

Authors:  Jun Young Kim; Gyeong-Hun Park; Min Ji Kim; Hyun Bo Sim; Weon Ju Lee; Seok-Jong Lee; Shin-Woo Kim; Young Hoon Jeon; Yong Hyun Jang; Do Won Kim
Journal:  Ann Dermatol       Date:  2018-02-21       Impact factor: 1.444

4.  Decreased absolute numbers of CD3+ T cells and CD8+ T cells during aging in herpes zoster patients.

Authors:  Li Wei; Jianguang Zhao; Wei Wu; Yu Zhang; Xuyan Fu; Lifeng Chen; Xiaoting Wang
Journal:  Sci Rep       Date:  2017-11-08       Impact factor: 4.379

5.  Impact of Zostavax Vaccination on T-Cell Accumulation and Cutaneous Gene Expression in the Skin of Older Humans After Varicella Zoster Virus Antigen-Specific Challenge.

Authors:  Neil P Patel; Milica Vukmanovic-Stejic; Mayte Suarez-Farinas; Emma S Chambers; Daisy Sandhu; Judilyn Fuentes-Duculan; Neil A Mabbott; Malcolm H A Rustin; James Krueger; Arne N Akbar
Journal:  J Infect Dis       Date:  2018-09-22       Impact factor: 5.226

Review 6.  Herpes Zoster and Immunogenicity and Safety of Zoster Vaccines in Transplant Patients: A Narrative Review of the Literature.

Authors:  Lei Wang; Erik A M Verschuuren; Coretta C van Leer-Buter; Stephan J L Bakker; Anoek A E de Joode; Johanna Westra; Nicolaas A Bos
Journal:  Front Immunol       Date:  2018-07-16       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.